Home › Research › Prevention and risk
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials
Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV et al.. JAMA, 2013-10-01
Topic: Risk, prevention and care in population studies
Results During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53). Results for other outcomes were similar to CEE plus MPA. For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P Conclusions and relevance Menopausal hormone therapy has a complex pattern of risks and benefits.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. https://doi.org/10.1001/jama.2013.278040
Vancouver
Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013. doi:10.1001/jama.2013.278040. PMID: 24084921.
BibTeX
@article{manson2013-24084921,
author = {Manson, J. E. and Chlebowski, R. T. and Stefanick, M. L. and Aragaki, A. K. and Rossouw, J. E. and Prentice, R. L. and Anderson, G. and Howard, B. V. and others},
title = {{Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials}},
journal = {JAMA},
year = {2013},
doi = {10.1001/jama.2013.278040},
pmid = {24084921},
url = {https://doi.org/10.1001/jama.2013.278040}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).
- Results for other outcomes were similar to CEE plus MPA.
- For CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P Conclusions and relevance Menopausal hormone therapy has a complex pattern of risks and benefits.
Why it matters
This report on menopausal hormone therapy found a complex pattern of risks and benefits, with some outcomes like breast cancer and heart disease showing increased risk during the intervention phase. It did not focus on dementia outcomes.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Participants8,506
- Evidence strengthLow
How this study scored 80/100
Published in a top-tier journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 3 / 4 | 8,506 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 7 / 7 | Cited 1,637 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 109.1 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | 6 / 6 | Cited 83.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 8 other studies in this library |
| Still being cited | 4 / 4 | Cited 377 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Robert B. Wallace: h-index 132 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 27 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24084921) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 80 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
8 studies in the alzhub library list this one in their references.
Related studies in Prevention and risk
Also in Prevention and risk
265 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.